NO330012B1 - Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom - Google Patents

Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom Download PDF

Info

Publication number
NO330012B1
NO330012B1 NO20050665A NO20050665A NO330012B1 NO 330012 B1 NO330012 B1 NO 330012B1 NO 20050665 A NO20050665 A NO 20050665A NO 20050665 A NO20050665 A NO 20050665A NO 330012 B1 NO330012 B1 NO 330012B1
Authority
NO
Norway
Prior art keywords
phenyl
oxo
pyrrolidine
carboxylic acid
benzyloxy
Prior art date
Application number
NO20050665A
Other languages
English (en)
Norwegian (no)
Other versions
NO20050665L (no
Inventor
Beat Wirz
Wolfgang Wostl
Rosa Maria Rodriguez Sarmiento
Andrew William Thomas
Rene Wyler
Synese Jolidon
Hans Iding
Daniela Krummenacher
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20050665L publication Critical patent/NO20050665L/no
Publication of NO330012B1 publication Critical patent/NO330012B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20050665A 2002-09-20 2005-02-08 Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom NO330012B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20
PCT/EP2003/010384 WO2004026827A1 (en) 2002-09-20 2003-09-18 Pyrrolidone derivatives as maob inhibitors

Publications (2)

Publication Number Publication Date
NO20050665L NO20050665L (no) 2005-04-18
NO330012B1 true NO330012B1 (no) 2011-02-07

Family

ID=32010924

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20050652A NO329754B1 (no) 2002-09-20 2005-02-08 Pyrrolidonderivater , farmasoytiske preparater inneholdende slike, slike forbindelserfor behandling av sykdommer samt anvendelse av medikamenter for behandling av skdom
NO20050665A NO330012B1 (no) 2002-09-20 2005-02-08 Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom
NO20050701A NO20050701L (no) 2002-09-20 2005-02-09 4-pyrrolidino-fenyl-benzyleter derivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20050652A NO329754B1 (no) 2002-09-20 2005-02-08 Pyrrolidonderivater , farmasoytiske preparater inneholdende slike, slike forbindelserfor behandling av sykdommer samt anvendelse av medikamenter for behandling av skdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20050701A NO20050701L (no) 2002-09-20 2005-02-09 4-pyrrolidino-fenyl-benzyleter derivater

Country Status (32)

Country Link
US (4) US7235581B2 (zh)
EP (3) EP1542969B1 (zh)
JP (3) JP4335141B2 (zh)
KR (3) KR100676015B1 (zh)
CN (3) CN100503562C (zh)
AR (3) AR041299A1 (zh)
AT (2) ATE472530T1 (zh)
AU (3) AU2003267381B2 (zh)
BR (4) BRPI0314631B1 (zh)
CA (3) CA2496756C (zh)
CY (1) CY1110745T1 (zh)
DE (2) DE60333202D1 (zh)
DK (1) DK1542970T3 (zh)
ES (2) ES2344557T3 (zh)
GT (3) GT200300206A (zh)
HK (3) HK1083499A1 (zh)
HR (3) HRP20050263B1 (zh)
JO (2) JO2605B1 (zh)
MX (3) MXPA05002880A (zh)
MY (3) MY134480A (zh)
NO (3) NO329754B1 (zh)
NZ (3) NZ538046A (zh)
PA (3) PA8583001A1 (zh)
PE (3) PE20050077A1 (zh)
PL (3) PL376019A1 (zh)
PT (1) PT1542970E (zh)
RU (3) RU2336267C2 (zh)
SI (1) SI1542970T1 (zh)
TW (3) TWI286132B (zh)
UY (3) UY27990A1 (zh)
WO (3) WO2004026827A1 (zh)
ZA (3) ZA200501137B (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
MX2007001169A (es) 2004-08-02 2007-03-12 Hoffmann La Roche Derivados de benciloxi como inhibidores de la oxidasa de monoamina b.
KR20070094666A (ko) 2005-02-25 2007-09-20 에프. 호프만-라 로슈 아게 약제 물질 분산성이 향상된 정제
KR100915736B1 (ko) * 2005-03-15 2009-09-04 에프. 호프만-라 로슈 아게 에난티오머 순수한 4-피롤리디노페닐, 벤질, 에터 유도체의제조 방법
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
EP1943216B1 (en) * 2005-10-10 2010-06-30 Glaxo Group Limited Prolinamide derivatives as sodium channel modulators
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US8372380B2 (en) * 2007-03-30 2013-02-12 The Regents Of The University Of California In vivo imaging of sulfotransferases
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
KR20150127172A (ko) 2013-03-14 2015-11-16 다트 뉴로사이언스 (케이만) 엘티디. Mao 억제제로서 치환된 나프티리딘 및 퀴놀린 화합물
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
RU2016118748A (ru) * 2013-10-29 2017-12-05 Ф. Хоффманн-Ля Рош Аг Кристаллические формы производного пирролидона, полезные при лечении болезни альцгеймера, и их получение
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
EP3273946A1 (en) 2015-03-27 2018-01-31 F. Hoffmann-La Roche AG Pharmaceutical formulation comprising sembragiline
JP7169592B2 (ja) 2017-09-27 2022-11-11 国立大学法人 鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痛薬
JP2020536870A (ja) 2017-10-05 2020-12-17 バイオジェン インコーポレイテッド アルファカルボキサミドピロリジン誘導体の調製方法
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
CA3092747A1 (en) * 2018-03-08 2019-09-12 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
EP3932490A4 (en) 2019-02-27 2022-11-16 Kagoshima University ANTIPRURIC AGENT USING PAC1 RECEPTOR ANTAGONISTS
US20230181587A1 (en) 2020-05-08 2023-06-15 Kagoshima University Antidepressant/anxiolytic drug in which pac1 receptor antagonist is used
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) * 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
EP0393607B1 (en) 1989-04-19 1996-02-21 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives having a hetero ring
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
CA2244253C (en) 1996-03-15 2002-11-12 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
CA2361848A1 (en) * 1999-04-02 2000-10-12 Dupont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase
AU1359801A (en) 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
MXPA02007649A (es) * 2000-02-10 2004-08-23 Potencia Medical Ag Tratamiento para la incontinencia urinaria con suministro de energia inalambrica.
DE60111019T2 (de) * 2000-02-14 2006-05-11 Potencia Medical Ag Penisprothese
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism

Also Published As

Publication number Publication date
HRP20050262A2 (en) 2006-06-30
HRP20050263B1 (hr) 2013-09-30
PE20050079A1 (es) 2005-03-01
AR041297A1 (es) 2005-05-11
BRPI0314631B1 (pt) 2018-04-17
PL376019A1 (en) 2005-12-12
NO20050665L (no) 2005-04-18
CN100503562C (zh) 2009-06-24
CA2498785C (en) 2011-07-26
AU2003267381A1 (en) 2004-04-08
GT200300205A (es) 2004-04-29
NZ538048A (en) 2007-05-31
MXPA05002880A (es) 2005-05-27
ATE459601T1 (de) 2010-03-15
AU2003270213A1 (en) 2004-04-08
ZA200501137B (en) 2006-12-27
US7037935B2 (en) 2006-05-02
JO2605B1 (en) 2011-11-01
DE60333202D1 (de) 2010-08-12
NO20050701L (no) 2005-03-02
AU2003273901B2 (en) 2008-07-10
TW200408624A (en) 2004-06-01
JO2604B1 (en) 2011-11-01
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
UY27991A1 (es) 2004-03-31
ZA200501311B (en) 2006-10-25
JP4335142B2 (ja) 2009-09-30
MY133332A (en) 2007-11-30
NO20050652L (no) 2005-03-08
WO2004026826A1 (en) 2004-04-01
NO329754B1 (no) 2010-12-13
NZ538046A (en) 2007-08-31
NZ538049A (en) 2007-05-31
RU2323209C2 (ru) 2008-04-27
RU2336267C2 (ru) 2008-10-20
HK1083499A1 (en) 2006-07-07
SI1542970T1 (sl) 2010-08-31
WO2004026825A1 (en) 2004-04-01
TW200410935A (en) 2004-07-01
MY134480A (en) 2007-12-31
CA2496756A1 (en) 2004-04-01
PA8583001A1 (es) 2004-04-23
AR041299A1 (es) 2005-05-11
TWI286132B (en) 2007-09-01
PL376018A1 (en) 2005-12-12
CN100383118C (zh) 2008-04-23
DE60331559D1 (de) 2010-04-15
PA8583501A1 (es) 2004-04-23
TW200413350A (en) 2004-08-01
US7122562B2 (en) 2006-10-17
US20040106650A1 (en) 2004-06-03
BR0314299A (pt) 2005-12-13
MY135696A (en) 2008-06-30
HK1083498A1 (en) 2006-07-07
KR20050057466A (ko) 2005-06-16
CN1681777A (zh) 2005-10-12
ZA200501557B (en) 2005-09-08
JP4335141B2 (ja) 2009-09-30
PE20050078A1 (es) 2005-02-28
HK1084383A1 (en) 2006-07-28
UY27993A1 (es) 2004-03-31
UY27990A1 (es) 2004-03-31
US20040097578A1 (en) 2004-05-20
JP2006503834A (ja) 2006-02-02
MXPA05002878A (es) 2005-05-27
PE20050077A1 (es) 2005-03-01
AU2003270213B8 (en) 2009-03-05
KR100676015B1 (ko) 2007-01-30
RU2005111968A (ru) 2006-11-10
HRP20050261A2 (en) 2006-05-31
CY1110745T1 (el) 2015-06-10
KR20050057450A (ko) 2005-06-16
US7151111B2 (en) 2006-12-19
EP1542971A1 (en) 2005-06-22
RU2336268C2 (ru) 2008-10-20
RU2005111969A (ru) 2006-01-20
RU2005111974A (ru) 2006-01-20
DK1542970T3 (da) 2010-08-02
EP1542969A1 (en) 2005-06-22
KR100681586B1 (ko) 2007-02-09
PL376021A1 (en) 2005-12-12
JP2006503833A (ja) 2006-02-02
AU2003273901A1 (en) 2004-04-08
AR041298A1 (es) 2005-05-11
US20060122235A1 (en) 2006-06-08
ES2344557T3 (es) 2010-08-31
US7235581B2 (en) 2007-06-26
GT200300204A (es) 2004-04-29
KR20050057456A (ko) 2005-06-16
CN1681779A (zh) 2005-10-12
ATE472530T1 (de) 2010-07-15
PT1542970E (pt) 2010-07-19
BR0314631A (pt) 2005-08-02
HRP20050263A2 (en) 2006-12-31
TWI337604B (en) 2011-02-21
GT200300206A (es) 2004-04-29
CN1681778A (zh) 2005-10-12
WO2004026827A1 (en) 2004-04-01
CA2496756C (en) 2012-01-10
KR100676014B1 (ko) 2007-01-30
ES2338646T3 (es) 2010-05-11
CN100400509C (zh) 2008-07-09
TWI331994B (en) 2010-10-21
US20040116707A1 (en) 2004-06-17
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
EP1542970B1 (en) 2010-06-30
JP4335140B2 (ja) 2009-09-30
BR0314314A (pt) 2005-07-26
JP2006510596A (ja) 2006-03-30
CA2498785A1 (en) 2004-04-01
CA2498335A1 (en) 2004-04-01
AU2003267381B2 (en) 2009-08-27
AU2003270213B2 (en) 2009-02-12
PA8583601A1 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
NO330012B1 (no) Pyrrolidonderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat inneholdende slike, slike forbindelser for behandling av sykdom samt anvendelse av slike for fremstilling av medikament for behandling av sykdom
US7485731B2 (en) Method for preparing enantiomerically pure 4-pyrrolidinophenylbenzyl ether derivatives
EP1761480A2 (en) New mao-b inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees